The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients

Korean Journal of Internal Medicine

Volumn 24, Issue 3, 2009, Pages 233-237

  Yoon, Hye Eun ^a   Song, Joon Chang ^a   Hyoung, Bok Jin ^a   Hwang, Hyeon Seok ^a   Lee, So Young ^a   Jeon, Youn Joo ^a   Choi, Bum Soon ^a   Kim, Yong Soo ^a   Yang, Chul Woo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Dyslipidemias; Ezetimibe; Kidney transplantation; Statin

Indexed keywords

C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CHOLESTEROL; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; PROTEINURIA; RASH; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AZETIDINES; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIMVASTATIN;

EID: 70449730901     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2009.24.3.233     Document Type: Article

References (28)

1. Massy ZA, Kasiske BL. Post-transplant hyperlipidemia: mechanisms and management. J Am Soc Nephrol 1996;7:971-977.
2. Jardine AG, Fellström B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005;46:529-536.
3. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996;7:158-165.
4. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004;4(Suppl 7):13-53.
5. Akhlaghi F, McLachlan AJ, Keogh AM, Brown KF. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 1997;44:537-542. (Pubitemid 27517479)
6. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-1948. (Pubitemid 35176299)
7. Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002; 89(5A): 50C-57C.
8. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-2134. (Pubitemid 36005898)
9. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24:717-728. (Pubitemid 36458984)
10. Ballantyne CM, Houri J, Notarbartolo A, LeBeaut AP, Sager P, Veltri EP. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409-2415. (Pubitemid 36605221)
11. Ose L, Johnson-Levonas A, Reyes R, et al. A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. Int J Clin Pract 2007;61:1469-1480. (Pubitemid 47228600)
12. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 2007;99:1706-1713. (Pubitemid 46874325)
13. Landray M, Baigent C, Leaper C, et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 2006;47:385-395.
14. Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga- Thie GM, Zwinderman AH, Jukema JW. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin 2008; 24:685-694.
15. Gagne C, Bays H, Weiss S, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-1091. (Pubitemid 35339435)
16. Sager PT, Melani L, Lipka L, et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414-1418. (Pubitemid 37532562)
17. Kastelein JJ, Akdim F, Stroes ES, et al. de Groot E Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443.
18. Bae JW, Kim HS, Lee SC, Han KH, Jeon ES. The safety and efficacy of ezetimibe and simvastatin combination therapy in Korean patients with primary hypercholesterolemia. Korean J Med 2005;68:487-497.
19. Puthenparumpil JJ, Keough-Ryan T, Kiberd M, Lawen J, Kiberd BA. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 2005;37:1033-1035. (Pubitemid 40590783)
20. Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation 2006;81:804-807.
21. Kohnle M, Pietruck F, Kribben A, Philipp T, Heemann U, Witzke O. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant 2006;6:205-208. (Pubitemid 43382220)
22. Buchanan C, Smith L, Corbett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006;6:770-774. (Pubitemid 43345015)
23. Pöge U, Gerhardt T, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005;5:1306-1311. (Pubitemid 40839418)
24. Holdaas H, Fellström B, Jardine AG, et al. Pedersen TR. Effect of fluvastation on cardiac outcomes in renal transplant recipients: a multi center, randomized, placebo-controlled trial Lancet 2003; 361:2024-2031.
25. Koshman SL, Lalonde LD, Burton I, Tymchak WJ, Pearson GJ. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 2005;39:1561-1565. (Pubitemid 41197143)
26. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44:467-494. (Pubitemid 40733733)
27. Bergman AJ, Burke J, Larson P, et al. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol 2006;46:328-336.
28. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI. Lenfant C ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 2002;33:2337-2341. (Pubitemid 35014654)